Literature DB >> 28314312

Surgical Resection for Pulmonary Metastasis from Pancreatic and Biliary Tract Cancer.

Tetsuzo Tagawa1,2, Kensaku Ito3, Kengo Fukuzawa4, Tatsuro Okamoto2, Atsuro Yoshimura4, Takahide Kawasaki4, Takashi Masuda4, Kentaro Iwaki4, Takahiro Terashi4, Masahiro Okamoto4, Akio Shiromizu4, Akira Motohiro3, Yoshihiko Maehara2.   

Abstract

AIM: To determine the efficacy of pulmonary metastasectomy for pancreatic and biliary tract cancer. PATIENTS AND METHODS: Ten patients who underwent therapeutic pulmonary metastasectomy after resection for pancreatic and biliary tract cancer at our Institution from 2006 to 2016 were retrospectively evaluated.
RESULTS: The primary site was the pancreas in four patients and biliary tract in six. Nine patients had single metastasis, and one patient had bilateral multiple metastases. The median time from surgery for the primary tumor to pulmonary resection was 23.3 months (range= 0-47.1 months). One patient underwent lobectomy, while nine patients underwent partial resection. One patient had incomplete resection due to pleural dissemination. There were no postoperative mortalities or major morbidities. The mean follow-up period was 26.0 months. The median survival time was 38.5 months, and the estimated 5-year overall survival was 38.9% after pulmonary resection. Five patients had recurrent disease after pulmonary resection, with a median recurrence-free interval of 6.0 months. One patient underwent second pulmonary resection for a solitary lung recurrence.
CONCLUSION: Despite the poor prognoses of these cancer types, pulmonary metastasectomy can significantly prolong survival in selected patients with pancreatic and biliary tract cancer. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Lung surgery; biliary tract cancer; metastatic lung tumor; pancreatic cancer

Mesh:

Year:  2017        PMID: 28314312     DOI: 10.21873/anticanres.11464

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both?

Authors:  Thomas L Sutton; Aaron Grossberg; Frederick Ey; Eileen M O'Reilly; Brett C Sheppard
Journal:  Cancer Biol Ther       Date:  2021-10-25       Impact factor: 4.742

2.  Outstanding Outcome of Pancreatic Cancer: What Lessons Do We Learn.

Authors:  Muhammad W Saif
Journal:  Pancreas (Fairfax)       Date:  2020-02-12

3.  Clinicopathological Features, Prognostic Factors and Survival in Patients With Pancreatic Cancer Bone Metastasis.

Authors:  Ying Ren; Shicheng Wang; Bo Wu; Zhan Wang
Journal:  Front Oncol       Date:  2022-02-09       Impact factor: 6.244

4.  Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report.

Authors:  Ryota Matsuki; Masanori Sugiyama; Hidefumi Takei; Haruhiko Kondo; Masachika Fujiwara; Junji Shibahara; Junji Furuse
Journal:  Surg Case Rep       Date:  2018-03-27

5.  Long-term survival after repeated resection for lung metastasis originating from pancreatic cancer: a case report.

Authors:  Yasunori Uesato; Koichi Tamashiro; Mitsuhisa Takatsuki
Journal:  Surg Case Rep       Date:  2020-04-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.